3 recruiting, 2 unknown, 1 active not recruiting, 1 completed. 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Kenny-Caffey syndrome, Type 1: new trials by email Literature Review of Kenny-Caffey syndrome, Type 1 trials Research Report on Kenny-Caffey syndrome, Type 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors SYN818 and Olaparib will be administered - Metastatic Solid Tumor, Ovarian Cancer | Phase 1 | Recruiting | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 110 | 2025-08-26 | 2025-09-05 |
| Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors Homologous Recombination Deficiency (HRD), ALK/ROS1/MET, standard care treatment - Advanced Solid Tumors, Metastatic Solid Tumors | Not applicable | Active not recruiting | National Cancer Center, Korea | 2800 | 2024-11-18 | 2026-10-23 |
| HRD Tests for Ovarian cancER tests to determine HRD status - Ovarian Cancer | Phase 2 | Recruiting | Centre Francois Baclesse | 88 | 2024-02-15 | 2025-09-17 |
| The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. Fluzoparib, Irinotecan - Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer | Phase 2 | Unknown | Fudan University | 29 | 2023-03-01 | 2023-02-24 |
| Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype Standard of care - Ovarian Cancer, Primary Peritoneal Cancer | Recruiting | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 1000 | 2022-12-01 | 2026-02-27 | |
| Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients PARP inhibitor - Ovarian Cancer, HRD | Unknown | Xiaoxiang Chen | 100 | 2021-09-15 | 2021-09-14 | |
| Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency PwO, PwCb, EC - Breast Cancer, Triple Negative Breast Neoplasms | Phase 2 | Completed | GBG Forschungs GmbH | 107 | 2016-09-01 | 2020-03-17 |
Ovarian Neoplasms (4) · Breast Neoplasms (2) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Gonadal Disorders (4) · Ovarian Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Breast Diseases (2)
Cyclophosphamide (1) · Epirubicin (1) · Irinotecan (1) · Poly(ADP-ribose) Polymerase Inhibitors (1) · Standard of Care (1) · Vernalization (1) · fluzoparib (1) · niraparib (1) · olaparib (1)
Centre Francois Baclesse (1) · Fudan University (1) · GBG Forschungs GmbH (1) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd (1) · National Cancer Center, Korea (1) · Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1) · Xiaoxiang Chen (1)
China (3) · Denmark (1) · France (1) · Germany (1) · South Korea (1)
Mansoor R Mirza, MD (1) · Xiaoxiang Chen, MD,PhD (1) · Young-Woo Kim (1)
PMID 25043054, PMID 27251275, PMID 27372738, PMID 33098995, PMID 35939768, PMID 38917788, PMID 40597907